atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
atai Life Sciences(NASDAQ: ATAI) (“atai” or “Company”), aclinical-stage biopharmaceutical company aiming to transform thetreatment of mental health disorders, today announced theappointment of Scott Braunstein, M.D., and Laurent Fischer, M.D.,as independent directors of atai’s supervisory board (“Board”)subject to applicable legal requirements.
Scott Braunstein, M.D., is the Chief ExecutiveOfficer (“CEO”) and Chairman of Marinus Pharmaceuticals, Inc. He isan operating partner at Aisling Capital and serves on the Board ofDirectors at both Caribou Biosciences, Inc. and Trevena Inc.Previously, Dr.Braunstein was Chief Operating Officer atPacira Pharmaceuticals, Inc. and portfolio manager of the JP MorganGlobal Healthcare Fund. Dr.Braunstein began his career as apracticing physician at the Summit Medical Group, earning hismedical degree from the Albert Einstein College of Medicine and hisundergraduate degree from Cornell University.
LaurentFischer, M.D., is the CEO andPresident of Adverum Biotechnologies and serves on the Board ofDirectors at Mirum Pharmaceuticals, Inc., Lycia Therapeutics andTeal. Previously, Dr.Fischer was Chairman of CTI Biopharma,CEO of Tobira Therapeutics (subsequently Allergan), and heldleadership roles at Jennerex, RXCentric (now part of AllscriptsHealthcare Solutions), MedVantx, Dupont Pharmaceuticals,Dupont-Merck, and F. Hoffmann-La Roche. Dr.Fischer earned anundergraduate degree from the University of Geneva and his medicaldegree from the Geneva Medical School, Switzerland.
Further, the Company announced that after fouryears of service, Jason Camm has stepped down from the Board.
Christian Angermayer, Founder and Chairman ofatai, said: “I am thrilled to welcome Scott and Laurent to atai’sBoard. Their remarkable achievements in the biopharmaceuticalsector and comprehensive understanding of drug development andcommercialization will be instrumental to our Board and managementteam as we advance into later-stage clinical trials. I also want tothank Jason for his invaluable contributions over the past fewyears.”
About atai Life Sciences
atai is a clinical-stage biopharmaceuticalcompany aiming to transform the treatment of mental healthdisorders and was founded as a response to the significant unmetneed and lack of innovation in the mental health treatmentlandscape. atai is dedicated to efficiently developing innovativetherapeutics to treat depression, anxiety, addiction, and othermental health disorders. By pooling resources and best practices,atai aims to responsibly accelerate the development of newmedicines to achieve clinically meaningful and sustained behavioralchange in mental health patients. atai's vision is to heal mentalhealth disorders so that everyone, everywhere can live a morefulfilled life. For more information, pleasevisitwww.atai.life.
Forward-looking Statements
This press release contains forward-lookingstatements within the meaning of the Private Securities LitigationReform Act of 1995, as amended. We intend such forward-lookingstatements to be covered by the safe harbor provisions forforward-looking statements contained in Section 27A of theSecurities Act of 1933, as amended (the “Securities Act”), andSection 21E of the Securities Exchange Act of 1934, as amended (the“Exchange Act”). The words “believe,” “may,” “will,” “estimate,”“continue,” “anticipate,” “intend,” “expect,” “anticipate,”“initiate,” “could,” “would,” “project,” “plan,” “potentially,”“preliminary,” “likely,” and similar expressions are intended toidentify forward-looking statements, although not allforward-looking statements contain these words. Forward-lookingstatements include express or implied statements relating to, amongother things: expectations regarding our supervisory board; ourbusiness strategy and plans; and the plans and objectives ofmanagement for future operations and capital expenditures.
Forward-looking statements are neither promisesnor guarantees, but involve known and unknown risks anduncertainties that could cause actual results to differ materiallyfrom those projected, including, without limitation, the importantfactors described in the section titled “Risk Factors” in our mostrecent Annual Report on Form 10-K filed with the Securities andExchange Commission (“SEC”), as such factors may be updated fromtime to time in atai's other filings with the SEC. atai disclaimsany obligation or undertaking to update or revise anyforward-looking statements contained in this press release, otherthan to the extent required by applicable law.
Contact Information
Investor Contact:
IR@atai.life
Media Contact:
PR@atai.life
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Apr 2024 to May 2024
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From May 2023 to May 2024
 | {{bbMessage.M_Alias}}{{bbMessage.MSG_Date}}{{bbMessage.HowLongAgo}}{{bbMessage.MSG_ID}}{{bbMessage.MSG_Subject}} |
Loading Messages....
News
Loading Messages....
`,data() {return {tabs: [] };},created() {this.tabs = this.$children;},methods: {selectTab(selectedTab) {this.tabs.forEach(tab => {tab.isActive = (tab.name == selectedTab.name);});}}});Vue.component('tab', {template: `
`,props: {name: { required: true },selected: { default: false}},data() {return {isActive: false};},computed: {href() {return '#' + this.name.toLowerCase().replace(/ /g, '-');}},mounted() {this.isActive = this.selected;}});Vue.component('newslist', {template: `
FEATURED
•{{ article.source }} • {{ article.date}} {{article.time}}
`,props: {source: { required: true },rawarticles: { required: true },limit: { default: 12 }},methods: {processData: function(articles){if(articles.length > this.limit){articles = articles.slice(0, this.limit);}this.articles = articles;this.loaded = true;Vue.nextTick(function(){});},stripRedudancies: function(articles){return _.uniqBy(articles, "headline");}},data() {return {loaded: false,articles: []};},mounted() {this.processData(this.rawarticles);}});new Vue({el: '#nw-news-widget',data: {loaded: false,availableTabs: {"Press Releases": [{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/atai-life-sciences-nv-ATAI\/stock-news\/93913868\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1716462617,"date":"Thu May 23, 2024 ","time":"7:10 AM (5 days ago)","full_date":"May 23, 2024 7:10 AM","post_time":"May 23 2024","article_id":93913868,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors","short_text":"NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences\u00a0(NASDAQ: ATAI) (\u201catai\u201d or \u201cCompany\u201d), a clinical-stage biopharmaceutical company aiming to transform the treatment of...","one_line_short_text":"NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences\u00a0(NASDAQ: ATAI) (\u201catai\u201d or \u201cCompany\u201d), a clinical-stage...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/atai-life-sciences-nv-ATAI\/stock-news\/93913712\/atai-life-sciences-strengthens-board-with-appointm","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1716462000,"date":"Thu May 23, 2024 ","time":"7:00 AM (5 days ago)","full_date":"May 23, 2024 7:00 AM","post_time":"May 23 2024","article_id":93913712,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Form 4 - Statement of changes in beneficial ownership of securities","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/atai-life-sciences-nv-ATAI\/stock-news\/93892662\/form-4-statement-of-changes-in-beneficial-owners","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1716240628,"date":"Mon May 20, 2024 ","time":"5:30 PM (1 week ago)","full_date":"May 20, 2024 5:30 PM","post_time":"May 20 2024","article_id":93892662,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/atai-life-sciences-nv-ATAI\/stock-news\/93855962\/form-10-q-quarterly-report-sections-13-or-15d","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1715773990,"date":"Wed May 15, 2024 ","time":"7:53 AM (2 weeks ago)","full_date":"May 15, 2024 7:53 AM","post_time":"May 15 2024","article_id":93855962,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/atai-life-sciences-nv-ATAI\/stock-news\/93855345\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1715771745,"date":"Wed May 15, 2024 ","time":"7:15 AM (2 weeks ago)","full_date":"May 15, 2024 7:15 AM","post_time":"May 15 2024","article_id":93855345,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates","short_text":"First participant dosed in Phase 1b trial of VLS-01 with data expected in 2H\u201924; Phase 2 study in TRD patients anticipated to initiate around YE\u201924Beckley Psytech\u2019s Phase 2a study of BPL-003 in...","one_line_short_text":"First participant dosed in Phase 1b trial of VLS-01 with data expected in 2H\u201924; Phase 2 study in TRD patients anticipated to initiate around...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/atai-life-sciences-nv-ATAI\/stock-news\/93855114\/atai-life-sciences-reports-first-quarter-2024-fina","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1715770798,"date":"Wed May 15, 2024 ","time":"6:59 AM (2 weeks ago)","full_date":"May 15, 2024 6:59 AM","post_time":"May 15 2024","article_id":93855114,"source_id":"globe","media_url":null,"press_release":true},{"headline":"atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech\u2019s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression","short_text":"The BPL-003 Phase 2a trial is an open-label study investigating BPL-003 as both monotherapy and adjunctive to SSRIs in patients with Treatment Resistant Depression.Initial results from the...","one_line_short_text":"The BPL-003 Phase 2a trial is an open-label study investigating BPL-003 as both monotherapy and adjunctive to SSRIs in patients with Treatment...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/atai-life-sciences-nv-ATAI\/stock-news\/93705395\/atai-life-sciences-announces-dosing-of-first-patie","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1713956438,"date":"Wed Apr 24, 2024 ","time":"7:00 AM (1 month ago)","full_date":"April 24, 2024 7:00 AM","post_time":"April 24 2024","article_id":93705395,"source_id":"globe","media_url":null,"press_release":true},{"headline":"atai Life Sciences Announces the Publication of Beckley Psytech\u2019s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology","short_text":"BPL-003 is Beckley Psytech\u2019s novel patent-protected benzoate salt formulation of 5-MeO-DMT that is administered intranasally.BPL-003 was shown to be safe and well-tolerated with a predictable...","one_line_short_text":"BPL-003 is Beckley Psytech\u2019s novel patent-protected benzoate salt formulation of 5-MeO-DMT that is administered intranasally.BPL-003 was shown to...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/atai-life-sciences-nv-ATAI\/stock-news\/93672196\/atai-life-sciences-announces-the-publication-of-be","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1713351601,"date":"Wed Apr 17, 2024 ","time":"7:00 AM (1 month ago)","full_date":"April 17, 2024 7:00 AM","post_time":"April 17 2024","article_id":93672196,"source_id":"globe","media_url":null,"press_release":true},{"headline":"atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights","short_text":"Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment paradigm established by Spravato\u00aeInitial...","one_line_short_text":"Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/atai-life-sciences-nv-ATAI\/stock-news\/93567854\/atai-life-sciences-reports-fourth-quarter-and-full","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1711623614,"date":"Thu Mar 28, 2024 ","time":"7:00 AM (2 months ago)","full_date":"March 28, 2024 7:00 AM","post_time":"March 28 2024","article_id":93567854,"source_id":"globe","media_url":null,"press_release":true},{"headline":"atai Life Sciences Announces Positive Initial Results from Beckley Psytech\u2019s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression","short_text":"- A single dose of BPL-003 demonstrated a rapid and durable antidepressant effect\u00a0in TRD patients, with 45% of patients in clinical remission at week 12 - 55% of patients achieved a clinical...","one_line_short_text":"- A single dose of BPL-003 demonstrated a rapid and durable antidepressant effect\u00a0in TRD patients, with 45% of patients in clinical remission at...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/atai-life-sciences-nv-ATAI\/stock-news\/93558671\/atai-life-sciences-announces-positive-initial-resu","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1711537233,"date":"Wed Mar 27, 2024 ","time":"7:00 AM (2 months ago)","full_date":"March 27, 2024 7:00 AM","post_time":"March 27 2024","article_id":93558671,"source_id":"globe","media_url":null,"press_release":true},{"headline":"atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01","short_text":"The Phase 1b trial of VLS-01 investigates the pharmaco*kinetics, pharmacodynamics, safety and tolerability of atai\u2019s proprietary, optimized oral transmucosal formulation of DMTVLS-01 is being...","one_line_short_text":"The Phase 1b trial of VLS-01 investigates the pharmaco*kinetics, pharmacodynamics, safety and tolerability of atai\u2019s proprietary, optimized oral...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/atai-life-sciences-nv-ATAI\/stock-news\/93411825\/atai-life-sciences-announces-first-participant-dos","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1709557218,"date":"Mon Mar 04, 2024 ","time":"8:00 AM (3 months ago)","full_date":"March 4, 2024 8:00 AM","post_time":"March 04 2024","article_id":93411825,"source_id":"globe","media_url":null,"press_release":true},{"headline":"atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference","short_text":"NEW YORK and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences\u00a0(NASDAQ: ATAI) (\u201catai\u201d), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health...","one_line_short_text":"NEW YORK and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences\u00a0(NASDAQ: ATAI) (\u201catai\u201d), a clinical-stage biopharmaceutical company...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/atai-life-sciences-nv-ATAI\/stock-news\/93382703\/atai-life-sciences-to-participate-in-the-upcoming","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1709157606,"date":"Wed Feb 28, 2024 ","time":"5:00 PM (3 months ago)","full_date":"February 28, 2024 5:00 PM","post_time":"February 28 2024","article_id":93382703,"source_id":"globe","media_url":null,"press_release":true}],"All News": [{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/atai-life-sciences-nv-ATAI\/stock-news\/93913868\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1716462617,"date":"Thu May 23, 2024 ","time":"7:10 AM (5 days ago)","full_date":"May 23, 2024 7:10 AM","post_time":"May 23 2024","article_id":93913868,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors","short_text":"NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences\u00a0(NASDAQ: ATAI) (\u201catai\u201d or \u201cCompany\u201d), a clinical-stage biopharmaceutical company aiming to transform the treatment of...","one_line_short_text":"NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences\u00a0(NASDAQ: ATAI) (\u201catai\u201d or \u201cCompany\u201d), a clinical-stage...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/atai-life-sciences-nv-ATAI\/stock-news\/93913712\/atai-life-sciences-strengthens-board-with-appointm","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1716462000,"date":"Thu May 23, 2024 ","time":"7:00 AM (5 days ago)","full_date":"May 23, 2024 7:00 AM","post_time":"May 23 2024","article_id":93913712,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Form 4 - Statement of changes in beneficial ownership of securities","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/atai-life-sciences-nv-ATAI\/stock-news\/93892662\/form-4-statement-of-changes-in-beneficial-owners","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1716240628,"date":"Mon May 20, 2024 ","time":"5:30 PM (1 week ago)","full_date":"May 20, 2024 5:30 PM","post_time":"May 20 2024","article_id":93892662,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/atai-life-sciences-nv-ATAI\/stock-news\/93855962\/form-10-q-quarterly-report-sections-13-or-15d","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1715773990,"date":"Wed May 15, 2024 ","time":"7:53 AM (2 weeks ago)","full_date":"May 15, 2024 7:53 AM","post_time":"May 15 2024","article_id":93855962,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"Form 8-K - Current report","short_text":"","one_line_short_text":"","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/atai-life-sciences-nv-ATAI\/stock-news\/93855345\/form-8-k-current-report","source":"Edgar (US Regulatory)","source_logo":"\/common\/images\/news-sources\/edgar2.png","tags":["REGULATORY"],"timestamp":1715771745,"date":"Wed May 15, 2024 ","time":"7:15 AM (2 weeks ago)","full_date":"May 15, 2024 7:15 AM","post_time":"May 15 2024","article_id":93855345,"source_id":"edgar2","media_url":null,"press_release":true},{"headline":"atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates","short_text":"First participant dosed in Phase 1b trial of VLS-01 with data expected in 2H\u201924; Phase 2 study in TRD patients anticipated to initiate around YE\u201924Beckley Psytech\u2019s Phase 2a study of BPL-003 in...","one_line_short_text":"First participant dosed in Phase 1b trial of VLS-01 with data expected in 2H\u201924; Phase 2 study in TRD patients anticipated to initiate around...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/atai-life-sciences-nv-ATAI\/stock-news\/93855114\/atai-life-sciences-reports-first-quarter-2024-fina","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1715770798,"date":"Wed May 15, 2024 ","time":"6:59 AM (2 weeks ago)","full_date":"May 15, 2024 6:59 AM","post_time":"May 15 2024","article_id":93855114,"source_id":"globe","media_url":null,"press_release":true},{"headline":"atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech\u2019s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression","short_text":"The BPL-003 Phase 2a trial is an open-label study investigating BPL-003 as both monotherapy and adjunctive to SSRIs in patients with Treatment Resistant Depression.Initial results from the...","one_line_short_text":"The BPL-003 Phase 2a trial is an open-label study investigating BPL-003 as both monotherapy and adjunctive to SSRIs in patients with Treatment...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/atai-life-sciences-nv-ATAI\/stock-news\/93705395\/atai-life-sciences-announces-dosing-of-first-patie","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1713956438,"date":"Wed Apr 24, 2024 ","time":"7:00 AM (1 month ago)","full_date":"April 24, 2024 7:00 AM","post_time":"April 24 2024","article_id":93705395,"source_id":"globe","media_url":null,"press_release":true},{"headline":"atai Life Sciences Announces the Publication of Beckley Psytech\u2019s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology","short_text":"BPL-003 is Beckley Psytech\u2019s novel patent-protected benzoate salt formulation of 5-MeO-DMT that is administered intranasally.BPL-003 was shown to be safe and well-tolerated with a predictable...","one_line_short_text":"BPL-003 is Beckley Psytech\u2019s novel patent-protected benzoate salt formulation of 5-MeO-DMT that is administered intranasally.BPL-003 was shown to...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/atai-life-sciences-nv-ATAI\/stock-news\/93672196\/atai-life-sciences-announces-the-publication-of-be","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1713351601,"date":"Wed Apr 17, 2024 ","time":"7:00 AM (1 month ago)","full_date":"April 17, 2024 7:00 AM","post_time":"April 17 2024","article_id":93672196,"source_id":"globe","media_url":null,"press_release":true},{"headline":"atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights","short_text":"Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment paradigm established by Spravato\u00aeInitial...","one_line_short_text":"Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/atai-life-sciences-nv-ATAI\/stock-news\/93567854\/atai-life-sciences-reports-fourth-quarter-and-full","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1711623614,"date":"Thu Mar 28, 2024 ","time":"7:00 AM (2 months ago)","full_date":"March 28, 2024 7:00 AM","post_time":"March 28 2024","article_id":93567854,"source_id":"globe","media_url":null,"press_release":true},{"headline":"atai Life Sciences Announces Positive Initial Results from Beckley Psytech\u2019s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression","short_text":"- A single dose of BPL-003 demonstrated a rapid and durable antidepressant effect\u00a0in TRD patients, with 45% of patients in clinical remission at week 12 - 55% of patients achieved a clinical...","one_line_short_text":"- A single dose of BPL-003 demonstrated a rapid and durable antidepressant effect\u00a0in TRD patients, with 45% of patients in clinical remission at...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/atai-life-sciences-nv-ATAI\/stock-news\/93558671\/atai-life-sciences-announces-positive-initial-resu","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1711537233,"date":"Wed Mar 27, 2024 ","time":"7:00 AM (2 months ago)","full_date":"March 27, 2024 7:00 AM","post_time":"March 27 2024","article_id":93558671,"source_id":"globe","media_url":null,"press_release":true},{"headline":"atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01","short_text":"The Phase 1b trial of VLS-01 investigates the pharmaco*kinetics, pharmacodynamics, safety and tolerability of atai\u2019s proprietary, optimized oral transmucosal formulation of DMTVLS-01 is being...","one_line_short_text":"The Phase 1b trial of VLS-01 investigates the pharmaco*kinetics, pharmacodynamics, safety and tolerability of atai\u2019s proprietary, optimized oral...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/atai-life-sciences-nv-ATAI\/stock-news\/93411825\/atai-life-sciences-announces-first-participant-dos","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1709557218,"date":"Mon Mar 04, 2024 ","time":"8:00 AM (3 months ago)","full_date":"March 4, 2024 8:00 AM","post_time":"March 04 2024","article_id":93411825,"source_id":"globe","media_url":null,"press_release":true},{"headline":"atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference","short_text":"NEW YORK and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences\u00a0(NASDAQ: ATAI) (\u201catai\u201d), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health...","one_line_short_text":"NEW YORK and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences\u00a0(NASDAQ: ATAI) (\u201catai\u201d), a clinical-stage biopharmaceutical company...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/atai-life-sciences-nv-ATAI\/stock-news\/93382703\/atai-life-sciences-to-participate-in-the-upcoming","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1709157606,"date":"Wed Feb 28, 2024 ","time":"5:00 PM (3 months ago)","full_date":"February 28, 2024 5:00 PM","post_time":"February 28 2024","article_id":93382703,"source_id":"globe","media_url":null,"press_release":true}],"Preferred Contributors": ""}},created: function () {this.loaded = true;Vue.nextTick(function(){});}});});
More News Articles
